NGAL is an effective early biomarker of AKI in a wide range of neonatal and pediatric intensive care scenarios (e.g. perinatal asphyxia [49], cardiac surgery [50]) predicting renal complications with good sensitivity as early as two days before sCr increase [51, 52]. This evidence concerns the gene LCN2 and acute kidney injury.